Rectacort - HC

Manufacturer
Acino Products, LLC.
Effective date
2014-06-19
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
1
Source
full-release
Hydrated at
2026-05-31 20:18:56

Label at a glance#

ProductRectacort - HC
Active ingredientHYDROCORTISONE ACETATE
Label structure12 sections

Indications and uses

Hydrocortisone acetate suppositories are indicated for the use in inflamed hemorrhoids, post-irradiation (factitial) proctitis; as an adjunct in the treatment of chronic ulcerative colitis; cryptitis; and other inflammatory conditions of anorectum and puritus ani.

Dosage and administration

For rectal administration. Detach one suppository from strip of suppositories. Remove the wrapper. Avoid excessive handling of the suppository which is designed to melt at body temperature. Insert suppository into the rectum with gentle pressure, pointed end first. Insert one suppository in the rectum twice daily, morning and night for two weeks, in nonspecific proctitis. In more severe cases, one suppository thre...

Label contents#

Full prescribing information#

DESCRIPTION:

DESCRIPTION SECTION

HYDROCORTISONE ACETATE, 25 mg

Rectal Suppositories

DESCRIPTION: Hydrocortisone Acetate is a corticosteroid designated chemically as pregn-4-ene-3, 20-dione, 21-(acetyloxy)-11, 17-dihydroxy-(11β) with the following structural formula:


Hydro Acetate Img labelHydro Acetate Img label

Each rectal suppository contains hydrocortisone acetate, USP 25 mg in a specially blended hydrogenated vegetable oil base.

CLINICAL PHARMACOLOGY:

CLINICAL PHARMACOLOGY SECTION

In normal subjects, about 26% of hydrocortisone acetate is absorbed when the suppository is applied to the rectum. Absorption of hydrocortisone acetate may vary across abraded or inflamed surfaces. Topical steroids are primarily effective because of their anti-inflammatory, anti-pruritic and vasconstrictive action.

INDICATIONS AND USAGE:

INDICATIONS & USAGE SECTION

Hydrocortisone acetate suppositories are indicated for the use in inflamed hemorrhoids, post-irradiation (factitial) proctitis; as an adjunct in the treatment of chronic ulcerative colitis; cryptitis; and other inflammatory conditions of anorectum and puritus ani.

CONTRAINDICATIONS:

CONTRAINDICATIONS SECTION

Hydrocortisone acetate suppositories are indicated for use in inflamed hemorrhoids, post-irradiation (factitial) proctitis; as an adjunct in the treatment of chronic ulcerative colitis; cryptitis; and other inflammatory conditions of anorectum and pruritus ani.

PRECAUTIONS:

PRECAUTIONS SECTION

Do not use hydrocortisone acetate suppositories unless a adequate proctologic examination is made.

If irritation develops, the product should be discontinued and appropriate therapy instituted.

In the presence of an infection, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, hydrocortisone acetate should be discontinued until the infection has been adequately controlled.

Carcinogenesis: No long term studies in animals have been performed to evaluate the carcinogenic potential of corticosteroid suppositories.

Pregnancy Category C: In laboratory animals, topical steroids have been associated with an increase in the incidence of fetal abnormalities when gestating females have been exposed to rather low dosage levels. There are no adequate and well controlled studies in pregnant women. Hydrocortisone acetate suppositories should only be used during pregnancy if the potential benefit justifies the risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.

It is not known whether this drug is excreted in human milk and because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from hydrocortisone acetate suppositories, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

ADVERSE REACTIONS:

ADVERSE REACTIONS SECTION

The following local adverse reactions have been reported with hydrocortisone acetate suppositories; burning, itching, irritation, dryness, folliculitis, hypopigmentation, allergic contact dermatitis, secondary infection.

DRUG ABUSE AND DEPENDENCE:

DRUG ABUSE AND DEPENDENCE SECTION

Drug abuse and dependence have not been reported in patients treated with hydrocortisone acetate suppositories.

OVERDOSAGE:

OVERDOSAGE SECTION

If signs and symptoms of systemic overdosage occur, discontinue use.

DOSAGE AND ADMINISTRATION:

DOSAGE & ADMINISTRATION SECTION

For rectal administration. Detach one suppository from strip of suppositories. Remove the wrapper. Avoid excessive handling of the suppository which is designed to melt at body temperature. Insert suppository into the rectum with gentle pressure, pointed end first. Insert one suppository in the rectum twice daily, morning and night for two weeks, in nonspecific proctitis. In more severe cases, one suppository three times a day or two suppositories twice daily. In factitial proctitis, the recommended duration of therapy is six to eight weeks or less, according to the response of the individual case.

HOW SUPPLIED:

HOW SUPPLIED SECTION

Hydrocortisone acetate suppository is off-white, smooth surfaced and rod shaped with one pointed end. Box of 12, 24, 50, 100 suppositories.

Store between 15°-30°C(59°-86°F). Protect from freezing

Rectacort-HC Product Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 68784-108-12

Rectacort - HC
25-mg Suppositories
(Hydrocortisone Acetate in a Hydrogenated Cocoglyceride Base)

Caution: Federal Law prohibits dispensing without prescription.

Place Rx Label Here

Acino Products

12 SUPPOSITORIES

DESCRIPTION: Each suppository contains hydrocortisone acetate 25 mg in a hydrogenated cocoglyceride base.

DIRECTIONS:
1. Detach one suppository from the strip of suppositories.
2. Remove wrapper before inserting into the rectum as follows: Hold suppository upright and carefully separate foil by inserting tip of fingernail at the foil split.
3. Peel slowly and evenly down both sides, exposing suppository.
4. Avoid excessive handling of suppository which is designed to melt at body temperature.
5. Insert one suppository rectally as directed in dosage and administration.

Store below 30°C (86°F). Avoid  freezing

DOSAGE AND ADMINISTRATION:
Usual Dosage: One suppository in the rectum morning and night for two weeks, in nonspecific procititis. In more severe cases, one suppository three times daily; or two suppositories twice daily in factitial proctitis, recommended therapy  is six  to eight weeks or less, according  to response. For full prescribing information, see packet insert.

ACINO PRODUCTS Hamilton, NJ 08619

Acino Rectacort HC12 LabelAcino Rectacort HC12 Label

Rectacort - HC Package Insert

SPL PATIENT PACKAGE INSERT SECTION

HYDROCORTISONE ACETATE, 25 mg

Rectal Suppositories

Manufactured by:
Acino Products, LLC
Hamilton, NJ 08691 Rev. 03/14


Rectacort Insert1 LabelRectacort Insert1 Label

Rectacort Insert2 LabelRectacort Insert2 Label

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
1291082hydrocortisone acetate 25 MG Rectal SuppositoryPSN1
1429379Rectacort-HC 25 MG Rectal SuppositoryPSN1
1429379hydrocortisone acetate 25 MG Rectal Suppository [Rectacort-HC]SBD1
1291082hydrocortisone acetate 25 MG Rectal SuppositorySCD1
1429379Rectacort-HC 25 MG Rectal SuppositorySY1

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
HYDROCORTISONE Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
15bd4439-874a-4934-9954-248e5455d460Product name120260310
9962b773-9f2e-22cc-0032-535e48ac417bProduct name320250724
56bb0587-1bf2-48b2-9d93-fc9f59d1eeb2Product name120250325
4d56e8eb-d741-d4a5-de3f-2bab1af75a60Product name720220608
626d7260-31b5-4412-84fd-579746adb6b3Product name120210513
8a011600-5e61-4c59-ab7b-54ab658a3b71Product name220181127
a919621a-248d-3c7a-1084-9f9ce286fdfdProduct name220181009
e7d5a174-836b-a0af-b014-cb0826c69ddcProduct name220181004
fcce390d-6460-4701-87cf-940d8800a1c3Product name220180212
bf065fa6-1e3b-e4c3-0bde-2dc842ceeea1Product name220150218
02657a3f-1489-66ea-f740-5ab9524e57d7Product name120140508
26f3d783-2cc1-4327-e77d-71804cf675a2Product name120140508
36fdc54c-bbeb-981e-8a53-4d768e283892Product name120140508
58f3f9b7-3b9b-a9c1-1c9f-18ac777192b8Product name120140508
61e59a42-186b-9f4b-aec3-fb49a6debc31Product name120140508
705740e1-dee5-2610-c5a3-4c59cd9d62afProduct name120140508
7bdc4804-3832-c0df-e519-72b6d47c9792Product name120140508
a7051cba-790b-a699-81f8-dbbbdbd9b5acProduct name120140508
abaf203f-619e-f265-559f-8c81af5cb1c2Product name120140508
acc4d8bb-0e29-e9f8-65f8-31e94184a9c0Product name120140508
b045ad64-0f28-9a02-2f9b-b34d94fb2278Product name120140508
bfd28ffb-d550-3fe9-f65b-10bcb7f971fdProduct name120140508
da108d9e-edc8-17a3-8c28-3251c6a8acccProduct name120140508
fe21f3fd-a378-0654-1972-db3c3b64470eProduct name120140508

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDCEffectiveActionDocumentIndexing SPLRelated label
68784-108-122019-11-27C16284748780-19855e2a2-3ad7-60a7-e053-dbdaa90a05bdaddb4490-6df1-4846-bd4b-5e987da15f23
68784-108-242019-11-27C16284748780-19855e2a2-3ad7-60a7-e053-dbdaa90a05bdaddb4490-6df1-4846-bd4b-5e987da15f23

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
68784-108-12Rectacort - HC1 in 1 BLISTER PACKSUPPOSITORY11
68784-108-12Rectacort - HC12 in 1 BOXSUPPOSITORY121
68784-108-24Rectacort - HC1 in 1 BLISTER PACKSUPPOSITORY11
68784-108-24Rectacort - HC24 in 1 BOXSUPPOSITORY241

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
68784-108RECTACORT - HC (HYDROCORTISONE ACETATE) SUPPOSITORY [ACINO PRODUCTS, LLC.]1Legacy NDC, 4 package rows20140627_addb4490-6df1-4846-bd4b-5e987da15f23.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
68784-108-12EA - Each68784-108248581eb-795c-42d0-9ba1-e993c9dd7b2f12014-07-02
68784-108-24EA - Each68784-10865133542-0b5a-49b9-964b-f9e8cf9d1fe612014-07-02

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
HYDROCORTISONE ACETATEACTIVE INGREDIENT3X7931PO741
HYDROCORTISONEACTIVE MOIETYWI4X0X7BPJ1
HYDROGENATED COCO-GLYCERIDESINACTIVE INGREDIENTXDD37N2GPR1

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 4 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
68784-10868784-108-12, 68784-108-24

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 2 matching rows.

Source Document#

Source XML

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
7b79a8c2-83a2-46ff-99bc-01b1c61bfd74addb4490-6df1-4846-bd4b-5e987da15f232014-06-19Adverse reactionsExact identifier
spl id: 7b79a8c2-83a2-46ff-99bc-01b1c61bfd74
spl set id: addb4490-6df1-4846-bd4b-5e987da15f23

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.